Shanghai Junshi Biosciences (HKG:1877, SHA:688180) obtained approval from Australia's Therapeutic Goods Administration (TGA) to market the drug toripalimab, according to a Hong Kong Stock Exchange disclosure on Jan. 17.
The TGA approved the new chemical entity application for toripalimab in combination with cisplatin and gemcitabine as a treatment for adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma or NPC.
Toripalimab was also approved as a single agent to treat adults with unresectable or metastatic NPC with disease progression on or after platinum-containing chemotherapy, the filing said.
The pharmaceutical company's Shanghai shares rose more than 1% and Hong Kong shares climbed less than 2% in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.